Search research articles
Contact Us
Filters
Showing results (61-70 of 112) with videos related to
Page
of 12
Sort By:
Gut
|
August 12, 2024
External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab
Nicolas Pierre, Vân Anh Huynh-Thu, Dominique Baiwir, et al.
Infection Prevention in Practice
|
January 5, 2023
Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study
Aurelien Amiot, Anne Bourrier, Jean-Marc Gornet, et al.
Alimentary Pharmacology & Therapeutics
|
June 21, 2021
Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort
Mathieu Uzzan, Clément Bresteau, David Laharie, et al.
Alimentary Pharmacology & Therapeutics
|
August 3, 2018
Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)
Charlotte Gagnière, Anne Bourrier, Philippe Seksik, et al.
Cancers
|
April 13, 2023
Preoperative Predictors of Neoplasia in Patients Undergoing Small Bowel Resection for Complicated Crohn's Disease: A Multicentre Case-Control Study
Capucine Chappe, Cecile Salut, Aurelien Amiot, et al.
Alimentary Pharmacology & Therapeutics
|
March 5, 2025
Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A GETAID Multicentre Cohort Study
Nicolas Richard, Aurélien Amiot, Philippe Seksik, et al.
Therapeutic Advances in Gastroenterology
|
August 9, 2024
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID
Bénédicte Caron, Philippe Seksik, Anthony Buisson, et al.
The American Journal of Gastroenterology
|
August 16, 2022
Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID
Gilles Boschetti, Maria Nachury, David Laharie, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 11, 2017
Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission
Catherine Reenaers, Jean-Yves Mary, Maria Nachury, et al.
Alimentary Pharmacology & Therapeutics
|
April 16, 2020
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study
Aurélien Amiot, Jérôme Filippi, Vered Abitbol, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 112) with videos related to
Sort By:
Page
of 12
Gut
|
August 12, 2024
External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab
Nicolas Pierre, Vân Anh Huynh-Thu, Dominique Baiwir, et al.
Infection Prevention in Practice
|
January 5, 2023
Risk of SARS-CoV-2 infection in healthcare workers with inflammatory bowel disease: a case-control study
Aurelien Amiot, Anne Bourrier, Jean-Marc Gornet, et al.
Alimentary Pharmacology & Therapeutics
|
June 21, 2021
Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort
Mathieu Uzzan, Clément Bresteau, David Laharie, et al.
Alimentary Pharmacology & Therapeutics
|
August 3, 2018
Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID)
Charlotte Gagnière, Anne Bourrier, Philippe Seksik, et al.
Cancers
|
April 13, 2023
Preoperative Predictors of Neoplasia in Patients Undergoing Small Bowel Resection for Complicated Crohn's Disease: A Multicentre Case-Control Study
Capucine Chappe, Cecile Salut, Aurelien Amiot, et al.
Alimentary Pharmacology & Therapeutics
|
March 5, 2025
Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A GETAID Multicentre Cohort Study
Nicolas Richard, Aurélien Amiot, Philippe Seksik, et al.
Therapeutic Advances in Gastroenterology
|
August 9, 2024
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID
Bénédicte Caron, Philippe Seksik, Anthony Buisson, et al.
The American Journal of Gastroenterology
|
August 16, 2022
Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID
Gilles Boschetti, Maria Nachury, David Laharie, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 11, 2017
Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission
Catherine Reenaers, Jean-Yves Mary, Maria Nachury, et al.
Alimentary Pharmacology & Therapeutics
|
April 16, 2020
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study
Aurélien Amiot, Jérôme Filippi, Vered Abitbol, et al.
Page
of 12